Covington has advised Gilead Sciences, Inc. CMS and Goodwin Procter have advised Tubulis GmbH. Gilead Sciences, Inc. has entered into a definitive agreement to acquire Tubulis...
Gilead to Acquire Tubulis in $5 Billion Oncology-Focused Transaction
Denali Therapeutics Enters $275 Million Synthetic Royalty Funding Agreement with Royalty Pharma
Gibson Dunn has advised Denali Therapeutics. Goodwin Procter and Maiwald have advised Royalty Pharma. Denali Therapeutics Inc. (Nasdaq: DNL) and Royalty Pharma plc (Nasdaq: RPRX) have...
AVROBIO’s Merger with Tectonic Therapeutic
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
Mercy BioAnalytics’ $41 Million Series A Financing
Goodwin advised Mercy BioAnalytics, Inc. on the deal. Mercy BioAnalytics, Inc. announced its $41 million Series A financing round. The financing was led by Novalis LifeSciences, with...